Third, in the first article the authors showed that ASPECTS predicts functional independence at 90 days in patients receiving intravenous thrombolytic therapy. 2 Interestingly, if we apply the same methodology, the present study would be negative (no statistical significant difference between ASPECTS Ͼ7 and Ͻ7 in the treatment arm for all primary and secondary outcomes) (Table) . In other words, contrary to authors conclusion, AS-PECTS is not useful in predicting functional independence in patients receiving intra-arterial thrombolysis.
How can the authors be sure that the published data are not the result of chance from multiple subgroups analyses?.
Although this tool could be useful in intravenous tissue plasminogen activator studies, some aspects of the ASPECTS score in intra-arterial thrombolysis remain to be elucidated. 
Gustavo Saposnik, MD

Response
We thank Dr Saposnik for his interest in ASPECTS for the assessment of baseline CT scans in patients with acute stroke. He raises a number of points to which we have the following responses.
ASPECTS was designed for the assessment of middle cerebral artery territory ischemia. This is not a limitation of the present study because the PROACT-II trial randomized only patients with proven occlusion in the middle cerebral artery. The fact that pro-urokinase is not licensed is not a limitation of the present study.
Unadjusted and Adjusted OR for Outcome Stratified by ASPECTS in the r-ProUK Treatment Arm
Because additional analyses from clinical trials do not usually assess randomized comparisons, these analyses are generally prone to confounding, not bias. Whereas confounding can be corrected by multivariable analyses, bias cannot. In our study, we adjusted the results for possible confounders using multivariable analysis. We acknowledge the concern about multiple testing. These analyses were post-hoc and were meant to be hypotheses generating, not confirmatory.
The original ASPECTS study 1 did not have a control group, but was a case series of stroke patients receiving intravenous tissue plasminogen activator. PROACT II, however, was a prospective, randomized, controlled study, and thus comparisons between r-proUK and control are the most appropriate. Nevertheless, Dr Saposnik has performed a subgroup analysis of his own and inadvertently has used odds ratios in reporting his findings. Odds ratios overestimate the true effect size when the outcome of interest is common, as in this case. The risk ratios for the proposed comparisons are shown in the Table. All of the comparisons involve a cohort of only 105 patients and hence the risk ratios have wide confidence intervals. Contrary to Dr Saposnik's assertion, ASPECTS is likely predictive of outcome and hemorrhage within this cohort of patients. The direction and effect size of the risk ratios are similar to what has been previously reported. [1] [2] [3] The fact that the risk ratios do not reach the conventional level of statistical significance, because of the small sample size, does not negate a plausible biological effect. In fact, these results support the notion that the ASPECTS is a robust scoring system for the assessment of baseline CT scans in patients with acute stroke that may be used to select the best candidates for intra-arterial thrombolysis. 
Outcome in the ProUK Cohort by ASPECTS Score
